RedHill Biopharma Ltd., an Israeli pharmaceutical company, has filed a Form D Notice of Exempt Offering of Securities with the United States Securities and Exchange Commission (SEC). The filing indicates a new notice for an offering with the date of first sale on January 25, 2024. RedHill Biopharma has successfully raised $10 million through the issuance of warrants to purchase up to 10 million American Depositary Shares at an exercise price of $1.00 per share. The offering, which did not last more than one year, included equity, options, warrants, and other rights to acquire securities. The company falls within the pharmaceuticals industry group and reported a revenue range of $5,000,001 to $25,000,000. The filing also lists several related persons, including executive officers and directors such as Dror...Show More

RedHill Biopharma Ltd., an Israeli pharmaceutical company, has filed a Form D Notice of Exempt Offering of Securities with the United States Securities and Exchange Commission (SEC). The filing indicates a new notice for an offering with the date of first sale on January 25, 2024. RedHill Biopharma has successfully raised $10 million through the issuance of warrants to purchase up to 10 million American Depositary Shares at an exercise price of $1.00 per share. The offering, which did not last more than one year, included equity, options, warrants, and other rights to acquire securities. The company falls within the pharmaceuticals industry group and reported a revenue range of $5,000,001 to $25,000,000. The filing also lists several related persons, including executive officers and directors such as Dror Ben-Asher, Razi Ingber, and others, all based at the company's principal place of business in Tel Aviv, Israel. The placement agent, H.C. Wainwright & Co., LLC, received warrants to purchase up to 600,000 ADSs of the company. No sales commissions or finder's fees were disclosed, and the proceeds are not intended for payments to any named executive officers, directors, or promoters.